Author Affiliations: Department of Ophthalmology (Drs Dalmon and Jeng) and Francis I. Proctor Foundation (Dr Jeng), University of California, San Francisco, and Department of Ophthalmology, San Francisco General Hospital (Dr Jeng), San Francisco, and The Permanente Medical Group, Walnut Creek (Dr Chandra).
Autologous serum eyedrops (ASEs) were first reported in the treatment of ocular disease in 1975 and have since been investigated in numerous ocular surface disorders.1 There are few studies from the United States, yet we know anecdotally that ASEs are used in tertiary care centers across the country.2 The lack of publicity about ASEs in the United States is, in large part, owing to unique barriers in implementing serum eyedrops as a standard treatment modality: laboratories must follow a manufacturing protocol in compliance with regulatory measures, patients must undergo phlebotomy, and patients must cover the cost. We report here a retrospective review of the first experience with ASEs in a large US patient population as an insurance-covered benefit.
We conducted a retrospective record review of all Kaiser Permanente Northern California (KPNC) members (population base of 3.2 million) who began treatment with ASEs for various ocular surface disorders from July 1, 2009, to June 30, 2010, by 11 KPNC cornea specialists. This study population represented all patients who received ASEs for the first time during the initial year in which ASEs were a covered benefit. The serum was collected at approved KPNC laboratories and prepared by Leiter's Compounding Pharmacy, San Jose, California. Institutional review board approval was granted by KPNC and the University of California, San Francisco Committee on Human Research.
Of the 103 patients treated during the study period, 18 were excluded because of prior use of ASEs and 12 were excluded for insufficient medical records, leaving 73 patients included in the study. There were 55 women and 18 men, with a mean age of 65 years. Sixty-nine patients received ASEs at a concentration of 100%. While many diseases were treated with ASEs, the leading indication for use was dry eye (Table). Among these patients with dry eye, who were typically recalcitrant to other treatments and often had concurrent indications, we identified 30 patients who had a follow-up visit within 90 days of initiating treatment with ASEs. In this group, 16 patients at the first follow-up visit and 11 at the last visit reported an improvement in symptoms with ASEs (average duration of treatment with ASEs, 8.8 months). Improved corneal staining was noted in 12 of these patients at the follow-up visit and in 13 at the last visit with ASEs. Additionally, topical lubrication use in this group decreased from 25 patients at the initial visit to 15 patients at the follow-up, and topical steroid use decreased from 10 patients to 5 patients (Figure).
Figure. Other ocular surface treatment modalities used by 30 patients with dry eye who had a follow-up within 90 days of starting treatment with autologous serum eyedrops (ASEs).
Seven of the 10 patients with persistent epithelial defects healed with the use of ASEs. The defect had been present for an average of 63 days prior to starting ASEs, and they healed within an average of 42 days. Of the 3 patients whose conditions did not resolve, 2 had perforation during the study period and 1 was lost to follow-up. We did not find a correlation between the duration of the defect prior to use of ASEs and the time to resolution (R2 = 0.07). Two patients reported transient discomfort with use of the ASEs.
We believe this represents the first study in which ASEs have been introduced as an insurance-covered benefit to a large and diverse US patient population. Our review supports previous reports on the safety and efficacy of ASEs, as many patients with recalcitrant dry eye symptoms improved with treatment by ASEs and used fewer local treatments.2- 6 The continued availability of ASEs may lower the threshold for KPNC members to receive ASEs, and further studies will provide us with information as to whether patients with less advanced disease or who receive earlier treatment derive as much benefit as those who are recalcitrant to standard treatment modalities.
Correspondence: Dr Chandra, The Permanente Medical Group, 320 Lennon Ln, Walnut Creek, CA 94598 (firstname.lastname@example.org).
Author Contributions: Dr Chandra had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Conflict of Interest Disclosures: None reported.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.